Navigation Links
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Date:3/31/2008

y 400% greater than the conversion rate for patients in

a comparable historical study who did not receive CETHRIN. When

analyzed as a subset, patients with cervical (neck) injuries who were

treated with CETHRIN showed improvement using the same impairment scale

that was almost 700% greater than the full patient group treated with

only the standard of care reported in the comparable study. In

subjects with cervical injuries, the interim efficacy data also suggest

that the conversion rate was dose-dependent.

-- In April and June 2007, Health Canada and the U.S. Food and Drug

Administration (FDA), respectively, authorized enrollment at an

increased dose level (9mg) in the CETHRIN Phase I/IIa clinical trial.

-- In January 2008, we ended enrollment in the CETHRIN Phase I/IIa

clinical trial. In total, 48 patients were enrolled at nine sites in

the United States and Canada. The results of the trial will continue

to be analyzed and communicated as the post-treatment evaluations are

completed.

-- At the end of 2007 and in early 2008, the Company met with the FDA,

Health Canada and the European Medicines Agency (EMEA), to review the

Phase I/IIa results and our CETHRIN clinical development plan. Based

on these discussions, Alseres plans to initiate a double-blind,

randomized, placebo-controlled, multi-center Phase IIb trial in up to

200 subjects with acute cervical SCI at up to 80 sites in the United

States, Canada, Europe and other selected countries during the second

half of 2008.

Presented results at major scientific and medical meetings.

During 2007, the Company presented data from its clinical programs at a

number of peer-reviewed scientific and medical meetings including:

-- Canadian Spine, March 2007;

-- American Association of Neurolog
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
4. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... BRAINTREE, Mass. , May 20, 2015  Haemonetics ... Brian Concannon , President & CEO, will present at ... New York on June 1 st , ... public may access Mr. Concannon,s presentation live via webcast ... Haemonetics Haemonetics (NYSE: HAE ) is a ...
(Date:5/20/2015)... SEATTLE , May 20, 2015  Resolution Bioscience ... of ctDx ALK TM , a blood-based liquid ... non-small cell lung carcinoma (NSCLC), the most common form ... the test to guide patients to personalized therapies and ... sample. The Department of Health, the CLIA ...
(Date:5/20/2015)... North Carolina , 20. Mai ... Unternehmen für klinische Logistik (Clinical Logistics ... das Geschäftsjahr 2014, das am 31. ... Das Unternehmen hat die Marktentwicklung übertroffen ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ., (GGI) ... announce they are donating 10,010 vaccines today in recognition ... effort and commitment of clinical trial volunteers who participated ... 2014. , With a mission to advance global ... participation, GGI supports International Clinical Trials Day and how ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... , NOVATO, Calif., June 10 BioMarin Pharmaceutical Inc. (Nasdaq: ... notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as ... Canada. Priority review provides for a shortened submission review ... plans to file a marketing application for Kuvan in Canada ...
... , MINNEAPOLIS, June 10 Charles A. Dinarello, M.D., a ... Medicine in Denver and a member of the Techne Corporation ... , , On April 26, 2009, Dr. Dinarello, ... Bruce Beutler, M.D., of The Scripps Research Institute , ...
... June 10 It doesn,t take long after,you,ve polished ... are,forcefully reminded of it in the restroom. Some people ... after urinating. The unmistakable olfactory,experience is caused by organic ... of our Podcast listeners on,Chemistry in our everyday life. ...
Cached Biology Technology:Kuvan Receives Priority Review Status From Health Canada 2Kuvan Receives Priority Review Status From Health Canada 3Kuvan Receives Priority Review Status From Health Canada 4Techne Corporation Board Member Recognized 2BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 2BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 3
(Date:4/27/2015)... Conn. , Apr. 27, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... commence shipping to pre-order customers the first week of ... through the month of May. ... a significant milestone for the company as Wocket® enters ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 26, 2013 MedNet Solutions , a global ... systems, is pleased to announce that Accelovance , ... early phase Oncology, Vaccines and General Medicine development, has ... Program .    Designation as an iMedNet Partner ...
... citrus greening, looms darkly over the United States, threatening ... fruit alone was valued at more than $3.4 billion ... by a University of California, Davis, plant scientist used ... how citrus greening impacts trees before they even show ...
... than $25 million over four years will help three ... of genomic variants relevant to human disease and the ... practice. The awards are from the National Institutes of ... sequencing the DNA of whole genomes (the body,s entire ...
Cached Biology News:MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 3New study offers hope for halting incurable citrus disease 2New study offers hope for halting incurable citrus disease 3New NIH-funded resource focuses on use of genomic variants in medical care 2New NIH-funded resource focuses on use of genomic variants in medical care 3
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Ultra-sensitive, non-radioactive detection of rat Big Endothelin-1 (Big ET-1)...
Qa-1 (L-12)...
Request Info...
Biology Products: